Protagonist Therapeutics, Inc.

PTGX

NASDAQ

Healthcare

Biotechnology

Newark, CA, US124 employeesprotagonist-inc.com

$103.85

+0.18(0.18%)

Mkt Cap $6.6B

$40.89

$105.40

52-Week Range

At A Glance

Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory ...

Revenue is primarily driven by Single Reportable Segment (100%).

Most recently: as Exhibit 99.1 hereto and is incorporated herein by reference. Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press rel (2026-02-25).

$6.6B

Market Cap

$46M

Revenue

-$131M

Net Income

Employees124

Fundamentals

How The Business Makes Money

Revenue by Segment

Single Reportable Segment100%($540M)

Activity

What Changed Recently

Financial Results

Feb 24, 2026

as Exhibit 99.1 hereto and is incorporated herein by reference. Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press rel

Regulation FD

Jan 11, 2026

. Regulation FD Disclosure. On January 12, 2026, Protagonist Therapeutics, Inc. (the “Company”) made available an updated corporate presentation. A copy of the

Peer Companies

Company	Price	Change	Market Cap	P/E
KYMRKymera Therapeutics, Inc.	$85.33	+0.47%	$7.0B	-20.9
ACLXArcellx, Inc.	$114.77	+0.02%	$6.7B	-28.2
ALKSAlkermes plc	$34.84	-0.58%	$5.8B	18.9
PTCTPTC Therapeutics, Inc.	$67.86	-1.30%	$5.6B	7.9
TGTXTG Therapeutics, Inc.	$33.51	-0.20%	$5.4B	9.7
IMVTImmunovant, Inc.	$24.67	-1.70%	$5.0B	-9.5
AKROAKRO	$54.65	+0.00%	$4.5B	—
VKTXViking Therapeutics, Inc.	$34.87	+5.79%	$4.0B	-10.3

Analyst View

Company Profile

CIK0001377121

ISINUS74366E1029

CUSIP74366E102

Phone510 474 0170

Address7707 Gateway Boulevard, Newark, CA, 94560-1160, US

SEC EDGAR